UK HealthCare | Strategic Alliance Partners

The growing role of biomarker-driven treatment selection in breast cancer and how pharmacists can help optimize therapy sequencing, toxicity management, and personalized care.

In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer.

In this segment, the experts turn their attention to metastatic HR+/HER2– breast cancer, examining the first results from the VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib.

Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.

In this segment, the experts dive into the monarchE subanalysis evaluating how Ki-67 levels before and after neoadjuvant chemotherapy inform prognosis and treatment planning for high-risk HR+, HER2– early breast cancer.

In this segment, the panel unpacks the 5-year results from the NATALEE trial, which evaluated ribociclib plus a nonsteroidal aromatase inhibitor in early HR+/HER2– breast cancer.

SABCS showcases emerging trends in breast cancer treatment, emphasizing pharmacists' vital role in medication management and patient care strategies.

New findings reveal a modest overall survival benefit of abemaciclib in early breast cancer, highlighting the importance of ongoing patient education and treatment strategies.

Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.

The FDA is modernizing its approach to drug development and optimization.

Terry Keys highlights the role of language and terminology as barriers for patients receiving cancer care.